<p>Wedbush 分析師 Martin Fan 今天維持了對 Sana Biotechnology 的買入評級，並設定了 7.00 美元的目標價。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並通過智能投資者精選升級到市場領先者的投資組合</li>
</ul>
<p>根據 TipRanks，Fan 是一位 5 星級分析師，平均回報率為 65.9%，成功率為 69.44%。Fan 關注醫療保健行業，主要分析 Nektar Therapeutics、Sana Biotechnology 和 Oruka Therapeutics 等股票。</p>
<p>在昨天發佈的一份報告中，美國銀行證券也重申了對該股票的買入評級，目標價為 7.00 美元。</p>

SANA

標普生物技術 3 倍做空 - Direxion

紐交所高增長板生物技術指數 ETF - First Trust

<p>Wedbush 分析師 Martin Fan 對 Sana Biotechnology (SANA) 維持了買入評級，目標價為 7.00 美元。Fan 是一位五星級分析師，成功率為 69.44%，專注於醫療保健領域。此外，美國銀行證券也重申了該股票的買入評級，目標價同樣為 7.00 美元</p>

<p>Wedbush analyst Martin Fan maintained a Buy rating on Sana Biotechnology today and set a price target of $7.00.</p>
<div class="lb-trans"><p>Wedbush 分析師 Martin Fan 今天維持了對 Sana Biotechnology 的買入評級，並設定了 7.00 美元的目標價。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並通過智能投資者精選升級到市場領先者的投資組合</li>
</ul>
</div><p>According to TipRanks, Fan is a 5-star analyst with an average return of 65.9% and a 69.44% success rate. Fan covers the Healthcare sector, focusing on stocks such as Nektar Therapeutics, Sana Biotechnology, and Oruka Therapeutics.</p>
<div class="lb-trans"><p>根據 TipRanks，Fan 是一位 5 星級分析師，平均回報率為 65.9%，成功率為 69.44%。Fan 關注醫療保健行業，主要分析 Nektar Therapeutics、Sana Biotechnology 和 Oruka Therapeutics 等股票。</p>
</div><p>In a report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $7.00 price target.</p>
<div class="lb-trans"><p>在昨天發佈的一份報告中，美國銀行證券也重申了對該股票的買入評級，目標價為 7.00 美元。</p>
</div>

Sana Biotechnology (SANA) Receives a Buy from Wedbush

Tip Ranks

Sana Biotechnology

Invesco Nasdaq Biotechnology ETF

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

醫藥突破 ETF - ALPS

內克塔治療

Oruka Therapeutics

美國銀行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Sana Biotechnology (SANA) 獲得了 Wedbush 的買入評級